Our Impact
We address some of the most significant challenges faced by modern medicine.
Our Approach
We are an Asian biologics company developing treatments for patients worldwide.
Our Focus
We develop series of innovative drug candidates for oncology and inflammatory disorders.
Our People
Our global team ensures a truly holistic approach to drug development.
Our Aim
To provide patients with breakthrough, life-saving and quality improving treatments.
Previous
Next

Company

Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. Developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide, we are devoted to being the leading Asian biologics company in advancing truly novel biologic products from pre-clinical studies to U.S. BLA submission and commercial launch.

Mission

Revolutionary remedies for a healthy and happy world.

Vision

Developing innovative medicines for patients worldwide. 

 

Values

Entrepreneurial

Value-driven

Integrity

Validation

Excellence

What’s Going On

Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.

Evive Biotech Announces Recent Appointments: VP of Biometrics and VP of Clinical Operations

Evive Biotech Announces IND Approval by the NMPA for a Phase II Clinical Study of F-652 in Patients with ACLF

Evive Biotech Announces the Appointment of Dr. Lichuan Liu as Senior VP, Global Head of Clinical and Translational Science

Evive Biotech Announces the Appointment of Dr. Weihai He as Senior VP, Global Head of Business Development

Evive Biotech and Sino Biopharm Subsidiary Announce Strategic Collaboration to Commercialize F-627 in China

Evive Biotech Announces the Appointment of Dr. Liping Sun as Senior VP, Global Head of R&D